Rigaku Launches Fourth Generation Handheld 1064 nm Raman Analyzer for Chemical Threat Analysis at IAFC HAZMAT 2025
12.6.2025 16:00:00 CEST | Business Wire | Press Release
Rigaku Analytical Devices, a division under Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami), announces the launch of its fourth generation 1064 nm Raman analyzers - the Icon series, featuring enhancements in chemical threat analysis for safety and security applications. The first in the series, the Icon-X, will be showcased at The International Hazardous Materials Response Teams Conference (HAZMAT), hosted by the International Association of Fire Chiefs (IAFC), in Baltimore, MD USA from June 13-14, 2025. From June 13 onward, we will begin rolling out global sales.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612450341/en/
Icon-X Image
The Icon-X is the first 1064 nm Raman analyzer to provide standoff chemical analysis allowing users to analyze potentially dangerous substances from a safe distance. This is critical for military, first responders, EOD, and border protection teams who could potentially be exposed to explosive threats, such as improvised explosive devices (IEDs), homemade explosives (HMEs), and chemical threats. This new, optional feature also reduces the need for time-consuming sample collection, while allowing responders to assess hazards without disrupting the scene.
In addition to the new standoff capability, the Icon-X contains an on-board, comprehensive library of chemical warfare agents (CWAs), explosives, narcotics, toxic industrial chemicals, precursors, cutting agents, and more. The Icon-X features a more ergonomic form factor, with improvements in all areas over previous generations, including:
- Use of the latest technology for enhanced processing
- Illuminated keypad and larger, more responsive touchscreen for easier use
- Optional GPS ability to mark critical scan data for fleet management and sensitive site exploitation
- Upgraded 13MP camera with LED flash for more clear images
- Meets the MIL-STD-810H standard for durability, passing tests for shock, pressure, and extreme temperatures. It also has IP68 certification, making it fully dustproof and waterproof—ideal for tough environments and decontamination use
- New accessories to expand applications, such as a ball probe to scan inside a deep container
As criminal networks become more sophisticated with easier access to chemicals and dangerous recipes, the need for first responders to have cutting-edge technology has never been more critical. Based on the success of Rigaku’s previous generations of handheld 1064 nm Raman technology, the Icon series provides users with reliable results, allowing them to respond faster, while keeping them safe from exposure. The utilization of 1064 nm Raman technology means users can scan through translucent packaging and identify dirty or mixed substances without fluorescence issues, a common issue for older Raman technology.
“While developing the Icon Series, we considered the years of feedback received from our global network of 1064 nm Raman users and partners,” said Dr. Michael Hargreaves, Vice President of Science & Technology at Rigaku Analytical Devices. “This allowed us to take a proven, field-accessible technology to the next level, and really expand the capabilities of handheld Raman spectroscopy. “
The Rigaku Icon-X will be demonstrated in booth #314 at the IAFC Hazmat Show in Baltimore, MD USA from June 13-14, 2025.
The Rigaku Icon-X joins the award-winning 1064 nm fleet of Rigaku CQL analyzers and is supported by Rigaku’s global sales and distribution channels. For more information on the Icon-X, please visit: www.rigakuanalytical.com.
About the Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit rigaku-holdings.com/english
About Rigaku Analytical Devices
Rigaku Analytical Devices is a pioneer in handheld 1064 nm Raman spectroscopy. Our products are trusted by law enforcement departments, government agencies, and security specialists to identify chemical threats. The pharmaceutical manufacturing sector relies on us for quality control. At Rigaku, we are focused on supporting our clients with our global expertise and developing innovative solutions that perform optimally, mitigate new chemical threats, and are always reliable and cost effective. Our rugged products deliver unparalleled accuracy and support for rapid lab-quality results any time, any place. For more information: http://www.rigakuanalytical.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612450341/en/
Contacts
Press Contact:
Sawa Himeno
Head of Communications Dept., Rigaku Holdings Corporation
prad@rigaku.co.jp
Tel: +81 90 6331 9843
Jen Lynch
Marketing Director, Rigaku Analytical Devices
Wilmington, MA USA
handhelds@rigaku.com
Tel: +1 781-328-1024
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom